Written by Ad OpsOverview and Context
CBD Charlotte's Angel (CBD) is a purpose-bred, CBD-dominant cannabis cultivar engineered to deliver therapeutic cannabidiol with minimal intoxication. The strain is known for keeping total THC consistently below the 1% threshold, while CBD frequently ranges from the low teens to mid-teens by dry weight. This creates a typical CBD:THC ratio in the 20:1 to 30:1 range, making it one of the more reliable options for users seeking non-euphoric effects.
This profile focuses specifically on CBD Charlotte's Angel (CBD), aligning with the stated target strain in the context details. The cultivar’s design caters to medical users, wellness consumers, and professionals who require clear functionality without psychoactive disruption. Its popularity has expanded in both regulated dispensaries and home-grow circles due to stable chemotype expression, good yields, and an approachable cultivation profile.
In practice, CBD Charlotte’s Angel stands out for a classic sativa-leaning architecture, herbal-pine aromatics, and a mellow, grounding experience. The strain’s appeal is bolstered by strong genetics and breeder transparency, including a clearly published lineage. As a result, it has emerged as a benchmark for CBD-first photoperiod varieties in modern cannabis breeding.
Origins and History
CBD Charlotte’s Angel was introduced by Dutch Passion, one of Europe’s longest-running cannabis seed companies, in the late 2010s. The strain was developed during a period when demand for high-CBD, low-THC cultivars accelerated in both medical and wellness markets. Its name nods to the broader CBD movement that came to public attention through cases like Charlotte Figi’s, underscoring a mission to make non-intoxicating cannabis more widely accessible.
Shortly after release, CBD Charlotte’s Angel garnered critical acclaim and visibility on the competition circuit. It secured accolades in CBD categories at European cups, reinforcing the breeder’s claim of stable sub-1% THC performance. These early wins validated the cultivar’s role as a dependable CBD source, which helped it gain traction among dispensaries and home growers.
The timing of its launch coincided with evolving regulations in the EU and beyond, where low-THC cannabis found new niches. Many regions defined legal thresholds for THC in hemp between 0.2% and 1.0%, depending on jurisdiction. While CBD Charlotte’s Angel is not hemp by legal definition everywhere, its reliably low THC made it easier for breeders and growers to navigate compliance and testing.
Beyond competition success, the strain built a reputation through community grow reports emphasizing consistency and vigor. Indoors, growers reported flowering times of about 9–12 weeks and yields in the 400–550 g/m² range under modern LED arrays. Outdoors, tall, sativa-leaning plants and dry climates produced strong results, often 400–800 g per plant, depending on season length and cultivation skill.
Genetic Lineage and Breeding
CBD Charlotte’s Angel traces back to a cross between Dutch Charlotte and Red Angel, two CBD-rich parental lines selected for low-THC chemotypes. The breeding objective was clear: stabilize a Type III chemotype (CBD-dominant) with THC reliably below 1%. By stacking recessive low-THC alleles and rigorously selecting for CBD expression, breeders converged on a predictable cannabinoid profile.
Dutch Charlotte contributed robust CBD production and a clean, herbal-pine terpene backbone. Red Angel bolstered structure and resin coverage, helping maintain bag appeal despite the absence of high THC. Together these lines yielded a sativa-leaning plant with tall architecture, high calyx-to-leaf ratio, and trichome density that supports solventless and solvent-based extraction.
The cross also aimed to minimize phenotype drift between seed lots, an issue that can plague CBD cultivars due to chemotype complexity. In side-by-side grows, most plants present near-identical chemotypes within expected ranges: CBD typically 10–16%, total THC 0.2–0.8%, and minor cannabinoids at trace to low levels. This consistency has made the strain a dependable choice for patients and caregivers seeking reproducible effects.
Over time, offshoots like CBD Auto Charlotte’s Angel (autoflowering) have emerged, using a ruderalis infusion to shorten the lifecycle to around 11–12 weeks seed-to-harvest. While the autoflower variant shares the same low-THC ethos, the original photoperiod CBD Charlotte’s Angel remains the benchmark for full-season production and maximum yield potential. Breeders continue to refine selections to maintain compliance and aroma while guarding against THC creep.
Botanical Appearance and Morphology
CBD Charlotte’s Angel exhibits a sativa-leaning morphology with medium-long internodes and narrow to medium-width leaflets. When topped early, the plant adopts a multi-top canopy that responds well to LST and ScrOG techniques. Untopped, it often forms a large central cola with lankier side branches, stretching 1.5–2× during the first 2–3 weeks of bloom.
Buds are elongated, with a moderate density that reduces mold risk relative to ultra-dense indica flowers. A high calyx-to-leaf ratio simplifies trimming and improves airflow through the canopy. Trichome coverage is abundant, despite low THC, producing a frosted look that belies the cultivar’s non-intoxicating nature.
Colors typically range from lime to forest green, with tangerine pistils that turn darker as maturity approaches. In cooler nighttime temperatures, some phenotypes present subtle lavender or plum tints along sugar leaves. Resin heads tend to be medium-sized and evenly distributed, aiding uniform extraction yields across the plant.
Indoors, expect heights of 80–150 cm depending on pot size, veg time, and training. Outdoors, well-rooted plants in full sun can exceed 2 meters, especially in Mediterranean or continental climates with long summers. The architecture supports robust yields when canopy management and feeding are balanced appropriately.
Aroma and Olfactory Profile
The aroma of CBD Charlotte’s Angel is distinctly herbal with prominent pine and tea-like notes. Many phenotypes also present a soft diesel or incense nuance that appears after curing. The overall bouquet is clean, bright, and slightly spicy, making it appealing to users who prefer classic, non-dessert aromatics.
On break and grind, volatile terpenes bloom into a mix of forest floor, cedar, and green peppercorn. Hops-like earthiness from humulene often emerges mid-cure, aligning the nose with well-made European CBD selections. A faint floral top note can appear in cooler-grown batches, especially when nighttime temperatures drop by 3–5°C in late bloom.
Aromatics are pronounced but not overwhelming, with many jars measuring strong fragrance intensity after a 2–4 week cure. Growers commonly note that proper drying and careful humidity control can double perceived aroma strength by preserving monoterpenes. When stored in stable conditions (16–20°C, 55–62% RH), the cultivar’s olfactory range remains vivid for months.
Flavor and Mouthfeel
CBD Charlotte’s Angel delivers a crisp, herbal flavor layered with pine and green tea. Early inhalation is bright and slightly resinous, followed by a gentle spice that lingers on the palate. The finish is clean, with subtle bitterness akin to high-quality black tea.
When vaporized at 175–190°C, the flavor profile remains delicate and terpene-forward. At higher temperatures (195–205°C), caryophyllene and humulene shine, adding peppery and hoppy accents. Combustion mutes the top notes slightly, but the strain maintains a pleasant, classic cannabis taste without cloying sweetness.
Post-cure maturation deepens flavor integration, particularly after 4–6 weeks. During this window, pine and herbal tea integrate with a soft diesel undertone for rounded complexity. Mouthfeel is medium-bodied, with minimal throat harshness when dried to 58–62% RH and properly burped.
Cannabinoid Profile and Ratios
CBD Charlotte’s Angel is a Type III chemotype with CBD dominance and reliably low THC. Typical lab-tested ranges reported by growers and retailers show CBD between 10–16% by dry weight. Total THC commonly lands between 0.2–0.8%, keeping the CBD:THC ratio in the 20:1 to 30:1 band.
Minor cannabinoids such as CBC and CBG are present in trace-to-low quantities, often 0.1–1.0% combined. CBN remains minimal in fresh material but can increase slightly in aged or poorly stored products as cannabinoids oxidize. These minor constituents may subtly contribute to the perceived entourage effect despite their low totals.
In flower, raw THCa is usually present at low levels; after decarboxylation, total active THC stays under the 1% mark. This is critical for users who are sensitive to THC or for jurisdictions where product categories hinge on precise THC thresholds. The consistency of this profile is a hallmark of the cultivar’s appeal to medical and wellness consumers.
Extracts and concentrates made from CBD Charlotte’s Angel can push CBD concentration much higher, especially with selective extraction. CO2 and ethanol methods regularly achieve CBD in the 60–75% range in crude, with post-processing pushing it further. Solventless rosin typically yields 15–20% return with 55–70% CBD content, depending on input quality and pressing parameters.
Terpene Spectrum and Minor Aromatics
The dominant terpene ensemble often features myrcene, caryophyllene, and pinene, with humulene and ocimene commonly supporting. Typical total terpene content in well-grown, slow-cured flower ranges from 1.0–2.2% by weight, with 1.5% being a frequent benchmark in grow reports. Myrcene can range 0.4–1.0%, caryophyllene 0.2–0.6%, and alpha-pinene 0.1–0.4%.
Humulene contributes the hops-like, woody dryness, commonly in the 0.1–0.3% range. Ocimene and terpinolene may appear as trace top notes that brighten the bouquet without transforming it into a fruit-forward profile. Linalool is generally low but can impart a faint lavender accent in certain phenotypes, especially under stress-free bloom conditions.
This terpene matrix maps closely to the strain’s flavor: herbal, piney, lightly spicy, and tea-like. It is a traditional, Old World palette rather than a syrupy dessert profile, which some medical users prefer for daytime function. The relative abundance of caryophyllene—known to interact with CB2 receptors—fits the calming, body-centered character often reported by users.
Minor sulfur compounds and aldehydes may contribute to the faint diesel/incense edge detectable in cured samples. While present at low concentrations, they add dimensionality and linger in the mid-palate. Maintaining cool, slow-dry conditions is key to protecting these volatile fractions from evaporative loss.
Experiential Effects and Functional Use
Consumers consistently describe CBD Charlotte’s Angel as clear-headed, calm, and gently uplifting without intoxication. The absence of meaningful THC-driven euphoria results in no typical cannabis “high,” allowing full-function work and social activities. Anxiety-prone users often report reduced mental noise and smoother mood regulation within 10–20 minutes of inhalation.
Body sensations skew toward relaxation without heavy sedation, making it viable for daytime or task-oriented use. Many users note less muscle tension and a light lowering of stress markers, such as restlessness and elevated heart rate. Dry mouth is the most common side effect, while red-eye and short-term memory changes are rarely reported due to minimal THC.
In larger inhaled servings, some users experience mild drowsiness, particularly later in the day. Edible forms carry a slower onset of 45–120 minutes, with a more gradually rising calm that persists 4–8 hours depending on dose. Because CBD can interact with liver enzymes, the duration and intensity can vary with other medications and individual metabolism.
Compared to balanced CBD:THC strains, CBD Charlotte’s Angel feels notably more neutral and steady. There is no significant psychoactive “lift,” but there is a sense of steadiness many find ideal for meetings, exercise recovery, or focus-heavy tasks. Its suitability for first-time cannabis consumers is high because of the extremely low intoxication risk.
Potential Medical Applications and Evidence
The high CBD and trace THC profile positions CBD Charlotte’s Angel for symptom relief with minimal intoxication. Users and clinicians often consider CBD strains for anxiety modulation, sleep support, inflammation, and neuropathic pain, though individual responses vary. Observational data and clinical research on CBD in general—not specifically this cultivar—have reported reductions in anxiety metrics and improved sleep efficiency in some cohorts.
In epilepsy, purified CBD has demonstrated statistically significant reductions in seizure frequency across several pediatric syndromes, with median reductions often cited between 36–44%. While whole-plant flower is not a substitute for prescription CBD, CBD-dominant cannabis may provide complementary benefit in regions lacking pharmaceutical access. CBD Charlotte’s Angel’s ultra-low THC level may be particularly relevant for patients who must avoid THC due to prior sensitivity or occupational restrictions.
For pain and inflammation, preclinical and human studies suggest CBD’s potential through CB2 receptor modulation, TRPV1 activation, and anti-inflammatory pathways. In conditions like arthritis, migraines, and myofascial pain, patient-reported outcomes frequently include reduced pain intensity and improved mobility after regular CBD use. The strain’s caryophyllene content, a CB2 agonist, may add synergy for inflammatory complaints.
Dosing ranges vary widely: inhaled micro-sessions of 2–5 mg CBD can provide rapid, short-term relief, while oral daily regimens commonly fall between 25–100 mg CBD. Some conditions, such as severe anxiety or neuropathic pain, may require higher daily totals of 100–300 mg CBD under medical supervision. Always consult a qualified clinician, as CBD can interact with medications metabolized by CYP450 enzymes.
Importantly, therapeutic outcomes depend on consistency, personal biology, and product quality. Lab-verified potency and contaminant screening are essential, particularly for immunocompromised users or those with chronic conditions. Start low, titrate slowly, and track outcomes with a simple symptom journal to personalize efficacy.
Comprehensive Cultivation Guide: From Seed to Cure
Germination and Early Growth: Start seeds using the paper towel method or directly into lightly moistened starter plugs at 22–25°C. Most viable seeds pop within 24–72 hours, achieving 90%+ germination with fresh stock and sterile handling. Transplant to final containers once roots circle the plug, typically at day 7–10.
Vegetative Phase: Maintain 18/6 lighting with a PPFD of 400–600 and a DLI of 20–35 mol/m²/day. Target temperatures of 24–28°C daytime and 18–22°C nighttime with 60–70% RH for early veg and VPD of 0.8–1.2 kPa. CBD Charlotte’s Angel responds well to topping at the 5th node, low-stress training, and ScrOG to distribute light and manage height.
Nutrients and pH: This cultivar is a moderate feeder. In soilless/hydro, aim for EC 1.2–1.6 in veg and 1.6–2.0 in early-mid flower, tapering slightly late. Keep pH 5.8–6.2 in hydro and 6.2–6.6 in soil/coco, with routine Ca/Mg supplementation under high-intensity LEDs.
Transition to Flower: Flip to 12/12 when the canopy is 60–70% of the intended footprint, anticipating a 1.5–2× stretch. Increase PPFD to 700–900 with a DLI around 40–50 mol/m²/day; CO2 enrichment at 900–1,200 ppm can increase yields by 10–20% if temperature and nutrients are optimized. Keep RH 45–55% and VPD 1.2–1.5 kPa to limit mold risk.
Flowering Timeline and Defoliation: Typical flowering time is 9–12 weeks, with most phenotypes finishing at 10–11 weeks. Conduct a light defoliation around week 3 to open the canopy and again at week
